What Makes Curis (CRIS) a New Buy Stock

A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years. Most Powerful Force Impacting Stock Prices Harnessing the Power of Earnings Estimate Revisions For the fiscal year ending December 2024, this drug developer is expected to earn -$5.39 per share, which is a change of 39.8% from the year-ago reported number. Curis ...